top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Sep 2
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
Aug 26
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Aug 12
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Aug 5
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Jul 31
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
May 6
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Dec 16, 2024
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 31, 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 6, 2024
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 14, 2024
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 9, 2024
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 24, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 2, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 9, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 2, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 25, 2023
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Mar 30, 2023
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
